Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers

Alexander J. Cammack, Nazem Atassi, Theodore Hyman, Leonard H. Van Den Berg, Matthew Harms, Robert H. Baloh, Robert H. Brown, Michael A. Van Es, Jan H. Veldink, Balint S. De Vries, Jeffrey D. Rothstein, Caroline Drain, Jennifer Jockel-Balsarotti, Amber Malcolm, Sonia Boodram, Amber Salter, Nicholas Wightman, Hong Yu, Alexander V. Sherman, Thomas J. EsparzaDiane McKenna-Yasek, Margaret A. Owegi, Catherine Douthwright, Alexander McCampbell, Toby Ferguson, Carlos Cruchaga, Merit Cudkowicz, Timothy M. Miller

Research output: Contribution to journalArticle

4 Scopus citations

Abstract

ObjectiveTo define the natural history of the C9orf72 amyotrophic lateral sclerosis (C9ALS) patient population, develop disease biomarkers, and characterize patient pathologies.MethodsWe prospectively collected clinical and demographic data from 116 symptomatic C9ALS and 12 non-amyotrophic lateral sclerosis (ALS) full expansion carriers across 7 institutions in the United States and the Netherlands. In addition, we collected blood samples for DNA repeat size assessment, CSF samples for biomarker identification, and autopsy samples for dipeptide repeat protein (DPR) size determination. Finally, we collected retrospective clinical data via chart review from 208 individuals with C9ALS and 450 individuals with singleton ALS.ResultsThe mean age at onset in the symptomatic prospective cohort was 57.9 ± 8.3 years, and median duration of survival after onset was 36.9 months. The monthly change was -1.8 ± 1.7 for ALS Functional Rating Scale-Revised and -1.4% ± 3.24% of predicted for slow vital capacity. In blood DNA, we found that G4C2 repeat size correlates positively with age. In CSF, we observed that concentrations of poly(GP) negatively correlate with DNA expansion size but do not correlate with measures of disease progression. Finally, we found that size of poly(GP) dipeptides in the brain can reach large sizes similar to that of their DNA repeat derivatives.ConclusionsWe present a thorough investigation of C9ALS natural history, providing the basis for C9ALS clinical trial design. We found that clinical features of this genetic subset are less variant than in singleton ALS. In addition, we identified important correlations of C9ALS patient pathologies with clinical and demographic data.

Original languageEnglish
Pages (from-to)E1605-E1617
JournalNeurology
Volume93
Issue number17
DOIs
StatePublished - Oct 22 2019

Fingerprint Dive into the research topics of 'Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers'. Together they form a unique fingerprint.

  • Cite this

    Cammack, A. J., Atassi, N., Hyman, T., Van Den Berg, L. H., Harms, M., Baloh, R. H., Brown, R. H., Van Es, M. A., Veldink, J. H., De Vries, B. S., Rothstein, J. D., Drain, C., Jockel-Balsarotti, J., Malcolm, A., Boodram, S., Salter, A., Wightman, N., Yu, H., Sherman, A. V., ... Miller, T. M. (2019). Prospective natural history study of C9orf72 ALS clinical characteristics and biomarkers. Neurology, 93(17), E1605-E1617. https://doi.org/10.1212/WNL.0000000000008359